Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0684249 (
lung carcinoma
)
23,830
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Currently, it is difficult to predict effective therapy response to molecular therapies for the treatment of lung cancer based solely on anatomical images.
31
P MR spectroscopic imaging could provide as a non-invasive method to monitor potential biomarkers for early therapy evaluation, a necessity to improve personalized care and reduce cost. However, surface coils limit the imaging volume in conventional
31
P MRSI. High-energetic adiabatic RF pulses are required to achieve flip angle homogeneity but lead to high SAR. Birdcage coils permit use of conventional amplitude modulated pulses, even over large FOV, potentially decreasing overall SAR massively. Here, we investigate the feasibility of 3D
31
P MRSI at 7 T in
lung carcinoma
patients using an integrated
31
P birdcage body coil in combination with either a dual-coil or a 16-channel receiver. Simulations showed a maximum decrease in SNR per unit of time of 8% for flip angle deviations in short TR low flip-angle excitation 3D
CSI
. The minimal SNR loss allowed for fast 3D
CSI
without time-consuming calibration steps (>10:00 min.).
31
P spectra from four
lung carcinoma
patients were acquired within 29:00 minutes and with high SNR using both receivers. The latter allowed discrimination of individual phosphodiesters, inorganic phosphate, phosphocreatine and ATP. The receiver array allowed for an increased FOV compared to the dual-coil receiver. 3D
31
P-
CSI
were acquired successfully in four
lung carcinoma
patients using the integrated
31
P body coil at ultra-high field. The increased spectral resolution at 7 T allowed differentiation of multiple
31
P metabolites related to phospholipid and energy metabolism. Simulations provide motivation to exclude
31
P B
1
calibrations, potentially decreasing total scan duration. Employing large receiver arrays improves the field of view allowing for full organ coverage.
31
P MRSI is feasible in
lung carcinoma
patients and has potential as a non-invasive method for monitoring personalized therapy response in lung tumors.
...
PMID:Feasibility of
31
P spectroscopic imaging at 7 T in lung carcinoma patients. 3173 67
